General Information of Drug (ID: DM8GFEV)

Drug Name
Atacicept Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 3 [1]
Lupus 4A40 Phase 2 [2]
Multiple sclerosis 8A40 Phase 2 [3]
Rheumatoid arthritis FA20 Phase 2 [3]
Systemic lupus erythematosus 4A40.0 Phase 2 [4]
Cross-matching ID
TTD Drug ID
DM8GFEV

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
A proliferation-inducing ligand (APRIL) TTOI1RM TNF13_HUMAN Modulator [1]

References

1 Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72.
2 ClinicalTrials.gov (NCT01972568) Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus. U.S. National Institutes of Health.
3 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)